Wanbury Limited has announced key board decisions regarding the re-appointment of its Independent Director and scheduling of an Extraordinary General Meeting. The pharmaceutical company's board meeting held on December 10, 2025, addressed important governance matters requiring shareholder approval.

Board Approves Director Re-appointment

The Board of Directors approved the re-appointment of Mr. Manojkumar Khubchand Gursahani (DIN: 01064558) as Non-Executive Independent Director. His current tenure is set to end on January 7, 2026, and the proposed re-appointment will be effective from January 8, 2026, to January 7, 2027.

Mr. Gursahani has confirmed that he continues to meet the criteria of independence under the provisions of the Companies Act, 2013, and the SEBI Listing Regulations.

Extraordinary General Meeting Scheduled

The board has approved the issuance of notice for convening an Extraordinary General Meeting (EGM) of shareholders. The meeting is scheduled for Monday, January 5, 2026, to seek necessary approval from shareholders for the re-appointment through a special resolution.

Director Profile and Experience

Mr. Manojkumar Khubchand Gursahani brings over 30 years of professional experience to the board. He is a distinguished thought leader holding a graduate degree from Mumbai University and serves as a TED speaker, global strategist, and author of "The Human Connect."

His professional accomplishments include:

• Co-founder of Vera Healthcare Technologies, an AI-driven platform for early detection of ocular diseases
• Executive Director at the Global Chamber
• Mumbai Chair for the Las Vegas Chamber of Commerce
• Managing Trustee of the Indian Relief Foundation
• Advisor to Lion Tarachand Bapa Hospital
• Immediate Past President of the Rotary Club of Queens Necklace, Mumbai

Compliance and Independence

The company has confirmed that Mr. Gursahani is not related to any of the directors of the company and is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. This ensures compliance with regulatory requirements for independent directors.

Meeting Details

The board meeting commenced at 4:30 PM and concluded at 5:15 PM on December 10, 2025. The company has informed both BSE Limited and National Stock Exchange of India about these decisions in accordance with Regulation 30 of the SEBI Listing Regulations.

Wanbury Limited , a prominent pharmaceutical company, has announced strong financial results for the second quarter and first half of fiscal year 2026, showcasing significant growth across key metrics.

Financial Highlights

The company reported impressive gains for H1FY26:

Q2FY26 Performance

For the second quarter of FY26, Wanbury reported:

• Revenue from Operations: 160.10 crore
• EBITDA: 26.00 crore, up 20.10% YoY
• EBITDA Margin: 16.20%, an improvement of 292 bps YoY
• PAT: 15.20 crore, showing a significant growth of 89.30% YoY
• PAT Margin: 9.50%, up from 4.90% in Q2FY25

Key Growth Drivers

The company's robust performance can be attributed to several factors:

1. Volume Growth: Increased sales volumes contributed to the revenue uptick.
2. Cost Efficiencies: Improved operational efficiency and cost management.
3. Product Yield Enhancement: Better production yields boosted profitability.
4. Lower Finance Costs: Reduced financial expenses positively impacted the bottom line.
5. Procurement Efficiencies: Optimized sourcing for raw materials and supplies.
6. Field Force Productivity: Enhanced sales team performance and promotional activities.

Strategic Initiatives

Wanbury has implemented several strategic initiatives to drive growth:

1. Digital Transformation: The company has implemented SAP S/4HANA Private Cloud, enhancing operational agility and data-driven decision-making.
2. New Product Introduction: Successfully launched a liposomal iron supplement.
3. Brand Promotion: Increased focus on various brand promotional activities.
4. Training Programs: Targeted training to improve sales force productivity.

Management Commentary

Mr. K S Rayana, Director of Wanbury Ltd., commented on the results: "Q2 continued our robust growth trajectory, with PAT of 15.20 crore in Q2 FY26, a 89.30% increase compared to 8.00 crore in Q2 FY25. This improvement was driven by cost efficiencies, improved product yield, and lower finance costs."

He further added, "Our efforts are aimed at strengthening Wanbury's position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders."

Future Outlook

Wanbury remains focused on:

1. Sustaining operational efficiencies
2. Expanding production capacities
3. Maintaining high-quality standards
4. Introducing new products
5. Strengthening its position in the global pharmaceutical market

The company's strong H1FY26 performance, coupled with its strategic initiatives, positions Wanbury for continued growth in the pharmaceutical sector.

Note: All financial figures are in Indian Rupees (₹) crore.